Article
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
PloS one - 1 Jan 2015
Chu Ying-Hsia, Li Huihua, Tan Hui Shan, Koh Valerie, Lai Johnathan, Phyo Wai Min, Choudhury Yukti, Kanesvaran Ravindran, Chau Noan Minh, Toh Chee Keong, Ng Quan Sing, Tan Puay Hoon, Chowbay Balram, Tan Min-Han
Abstract excerpt
Sunitinib is a tyrosine kinase inhibitor used as first-line treatment for metastatic renal cell carcinoma (mRCC). Asian ethnicity has been previously associated with lower clearance and greater toxicities for sunitinib treatment, relative to Caucasian ethnicity. Research focusing on identifying corresponding biomarkers of efficacy and toxicity has been hitherto conducted in Caucasian populations, and few of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
